Miranda Jayne Toledano net worth and biography

Miranda Toledano Biography and Net Worth

CEO of Entera Bio

Miranda Toledano has served as a member of our Board of Directors since 2018 and as prior Chair of the Audit Committee. Ms. Toledano has served as Entera’s Chief Executive Officer since July 2022. Ms. Toledano has over 25 years of C-level leadership, principal investment and Wall Street/capital market experience in the biotech sector. Previously, Miranda served as Chief Operating Officer, Chief Financial Officer, and Board Member of TRIGR Therapeutics, a stealth oncology focused, clinical stage bispecific antibody company, from August 2018 until its acquisition by Compass Therapeutics (Nasdaq: CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development of lead asset TR009 (now CTX-009, tovecimig) and led strategic execution, including a $117 million China License Transaction and TRIGR’s 2021 acquisition by Compass. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma (Nasdaq: RPRX) from 2004 to 2010. Ms. Toledano is also a member of the board of directors of Journey Medical (Nasdaq: DERM). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

What is Miranda Jayne Toledano's net worth?: The estimated net worth of Miranda Jayne Toledano is at least $1.39 million as of December 29th, 2025. Toledano owns 426,575 shares of Entera Bio stock worth more than $1,390,635 as of July 29th. This net worth approximation does not reflect any other assets that Toledano may own. Learn More about Miranda Jayne Toledano's net worth.
How do I contact Miranda Jayne Toledano?: The corporate mailing address for Toledano and other Entera Bio executives is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. Entera Bio can also be reached via phone at (722) 532-7151 and via email at [email protected]. Learn More on Miranda Jayne Toledano's contact information.
Has Miranda Jayne Toledano been buying or selling shares of Entera Bio?: Miranda Jayne Toledano has not been actively trading shares of Entera Bio during the last quarter. Most recently, on Monday, December 29th, Miranda Jayne Toledano bought 11,000 shares of Entera Bio stock. The stock was acquired at an average cost of $1.81 per share, with a total value of $19,910.00. Following the completion of the transaction, the chief executive officer now directly owns 426,575 shares of the company's stock, valued at $772,100.75. Learn More on Miranda Jayne Toledano's trading history.
Who are Entera Bio's active insiders?: Entera Bio's insider roster includes Geno Germano (Director), Yonatan Malca (Director), Ron Mayron (Director), Ramesh Ratan (CFO), and Miranda Toledano (CEO). Learn More on Entera Bio's active insiders.
Are insiders buying or selling shares of Entera Bio?: In the last year, Entera Bio insiders bought shares 5 times. They purchased a total of 69,000 shares worth more than $92,530.00. The most recent insider tranaction occured on March, 9th when Director Geno J Germano bought 20,000 shares worth more than $26,000.00. Insiders at Entera Bio own 10.6% of the company. Learn More about insider trades at Entera Bio.
Information on this page was last updated on 3/9/2026.

Miranda Jayne Toledano Insider Trading History at Entera Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/29/2025	Buy	11,000	$1.81	$19,910.00	426,575
12/22/2023	Buy	23,952	$0.71	$17,005.92	110,752
4/4/2023	Buy	30,000	$1.01	$30,300.00	86,800
11/11/2022	Buy	50,000	$0.53	$26,500.00	56,800

Miranda Jayne Toledano Buying and Selling Activity at Entera Bio

Entera Bio Company Overview

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $3.29

$3.10

$3.30

50 Day Range

MA: $1.58

$1.16

$3.92

2 Week Range

Now: $3.29

$0.91

$4.20

Volume

547,553 shs

Average Volume

1,188,364 shs

Market Capitalization

$162.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.43